01:49 AM EDT, 10/08/2026 (MT Newswires) -- GenSight Biologics (SIGHT.PA) raised 1 million euros from an offering of shares and warrants, including pre-funded warrants, to two existing shareholders, Heights Capital and Invus. The French clinical-stage biotechnology company issued 2,597,404 ordinary shares, 11,940,300 pre-funded warrants, and 14,537,704 warrants, with investors having the right to choose a combination of shares and warrants or pre-funded warrants and warrants in a 1:1 ratio, according to a Thursday release. The shares will begin trading on Euronext Paris on Oct. 12. Proceeds will be used for operating activities and working capital, pending the structural financing of the Recover phase III trial.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.